About
Steve Favaloro is a biotech executive, board member, and investor who serves as an executive advisor at Ampersand Capital Partners. He is Chairman and CEO of Genezen, a gene and cell therapy CDMO, and previously held CFO roles at Arbor Biotechnologies, Arranta Bio (acquired by Recipharm in 2022), and Brammer Bio (sold to Thermo Fisher Scientific in 2019), along with earlier finance roles at MilliporeSigma, Merck KGaA, and Bruker Corporation. He holds an MBA and MS from the Carroll School of Management at Boston College and a BA in Economics from Boston College.
Invests in
Biotech
Investments
Board seats
BiologosVernal Bio
Per the firm's website.
Colleagues at Ampersand
Aditya V. Goel
Associate at Ampersand
Benoit P. Bouche
Operating Partner at Ampersand
Cole S. Aldrich
Senior Associate at Ampersand
David Q. Anderson
General Partner at Ampersand
Dean D. Schauer
Operating Partner at Ampersand
Elias J. Laimboeck
Senior Associate at Ampersand
Emanuele M. Delfino
Associate at Ampersand
Eric B. Lev
General Partner at Ampersand
Frequently asked questions
- Who is Steve Favaloro?
- Steve Favaloro is a biotech executive, board member, and investor who serves as an executive advisor at Ampersand Capital Partners. He is Chairman and CEO of Genezen, a gene and cell therapy CDMO, and previously held CFO roles at Arbor Biotechnologies, Arranta Bio (acquired by Recipharm in 2022), and Brammer Bio (sold to Thermo Fisher Scientific in 2019), along with earlier finance roles at MilliporeSigma, Merck KGaA, and Bruker Corporation. He holds an MBA and MS from the Carroll School of Management at Boston College and a BA in Economics from Boston College.
- Where does Steve Favaloro work?
- Steve Favaloro is Executive Advisor at Ampersand.
- What does Steve Favaloro invest in?
- Steve Favaloro invests in Biotech.
- What boards does Steve Favaloro sit on?
- Steve Favaloro holds tracked board seats at Biologos, Vernal Bio.